John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVEE
1551
DELISTED
NV5 Global
NVEE
| $1.73M | ﹤0.01% |
+70,504
| New | +$1.83M |
|
1552
HealthStream
HSTM
$846M
| $1.73M | ﹤0.01% |
64,779
-1,609
| -2% | -$43K |
|
1553
Taboola.com
TBLA
$1B
| $1.73M | ﹤0.01% |
388,926
+238,528
| +159% | +$1.06M |
|
1554
Citi Trends
CTRN
$561M
| $1.72M | ﹤0.01% |
63,487
+18,603
| +41% | +$536K |
|
1555
Preferred Bank
PFBC
$1.23B
| $1.72M | ﹤0.01% |
22,431
-22,478
| -50% | -$1.63M |
|
1556
American Financial Group
AFG
$11.9B
| $1.72M | ﹤0.01% |
12,600
-87,879
| -87% | -$10.9M |
|
1557
ZTO Express
ZTO
$16.2B
| $1.72M | ﹤0.01% |
82,000
-1,384,087
| -94% | -$26.5M |
|
1558
Strategy Inc
MSTR
$50.5B
| $1.71M | ﹤0.01% |
10,050
-746,010
| -99% | -$68M |
|
|
HDSN
1559
Hudson Technologies
HDSN
$230M
| $1.71M | ﹤0.01% |
154,960
-133,787
| -46% | -$1.74M |
|
1560
Infosys
INFY
$48.7B
| $1.71M | ﹤0.01% |
95,100
-948,207
| -91% | -$18.4M |
|
1561
Design Therapeutics
DSGN
$976M
| $1.7M | ﹤0.01% |
422,035
-6,136
| -1% | -$16.4K |
|
1562
Patterson-UTI
PTEN
$4.41B
| $1.7M | ﹤0.01% |
142,290
-779,906
| -85% | -$8.66M |
|
|
YMAB
1563
DELISTED
Y-mAbs Therapeutics
YMAB
| $1.7M | ﹤0.01% |
104,302
+42,463
| +69% | +$572K |
|
1564
Columbus McKinnon
CMCO
$513M
| $1.69M | ﹤0.01% |
37,912
-47,421
| -56% | -$1.92M |
|
1565
Wintrust Financial
WTFC
$10.2B
| $1.69M | ﹤0.01% |
16,200
-1,200
| -7% | -$116K |
|
|
MITT
1566
TPG Mortgage Investment Trust
MITT
$213M
| $1.69M | ﹤0.01% |
275,767
+47,699
| +21% | +$293K |
|
1567
Deere & Co
DE
$170B
| $1.68M | ﹤0.01% |
4,100
-30,211
| -88% | -$11.6M |
|
1568
Ocugen
OCGN
$475M
| $1.68M | ﹤0.01% |
1,026,008
+868,704
| +552% | +$728K |
|
1569
Esquire Financial Holdings
ESQ
$1.37B
| $1.67M | ﹤0.01% |
35,279
+13,454
| +62% | +$659K |
|
|
VGR
1570
DELISTED
Vector Group Ltd.
VGR
| $1.67M | ﹤0.01% |
152,078
-43,921
| -22% | -$477K |
|
|
DVAX
1571
DELISTED
Dynavax Technologies
DVAX
| $1.66M | ﹤0.01% |
133,809
-9,573
| -7% | -$125K |
|
1572
Quaker Houghton
KWR
$2.83B
| $1.65M | ﹤0.01% |
8,063
+1,523
| +23% | +$302K |
|
1573
White Mountains Insurance
WTM
$5.09B
| $1.65M | ﹤0.01% |
922
+500
| +118% | +$838K |
|
1574
Fulcrum Therapeutics
FULC
$296M
| $1.65M | ﹤0.01% |
175,224
-86,528
| -33% | -$772K |
|
1575
State Street SPDR Portfolio S&P 600 Small Cap ETF
SPSM
$17.1B
| $1.65M | ﹤0.01% |
+38,382
| New | +$1.59M |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.